United Kingdom: Food and Drugs Law

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
Life Sciences Patents Monthly Roundup—July 2026
This monthly roundup examines critical patent law developments across multiple jurisdictions, including landmark UPC Court of Appeal decisions on preliminary injunctions and urgency requirements, French and Belgian court rulings on supplementary protection certificates and biosimilar equivalence, and UK guidance on expedition applications in pharmaceutical patent disputes. The analysis explores how courts are interpreting infringement standards, evidence production alignment in parallel proceedings, and the
Worldwide IP
AO
A&O Shearman
Article
When Is A Synbio Company A Gene Therapy Company?
The UK's medicines regulator is proposing fundamental changes to how gene therapy products are defined, shifting from origin-based classifications to mechanism-driven frameworks. This consultation raises critical questions about where regulatory boundaries will be drawn for synthetic biology, genome editing platforms, and engineered cell therapies as biotechnology advances beyond traditional biological manufacturing.
United Kingdom Healthcare
PC
Potter Clarkson
Article
Family Calls For Better Understanding Of Ketamine Addiction To Help Reduce Drug-related Deaths
A mother shares the heartbreaking story of her 22-year-old daughter's death from ketamine addiction, revealing how recreational drug use spiraled into a debilitating condition called ketamine bladder that caused chronic pain and ultimately led to fatal complications. The case exposes critical gaps in healthcare support for ketamine addiction and raises urgent questions about education, treatment pathways, and the accessibility of this Class B substance.
United Kingdom Healthcare
RB
Rothera Bray
Article
EU Agrees To Delay Key AI Act Compliance Deadlines
The European Union has reached a political agreement to significantly extend compliance deadlines for high-risk AI systems under the AI Act, with businesses now having until December 2027 or August 2028 depending on their category. The revised framework introduces separate timelines for different types of high-risk AI applications, narrows certain definitions, and provides regulatory relief for small and medium-sized companies while adding new prohibitions on non-consensual intimate content generation.
United Kingdom Technology
TS
Travers Smith LLP
See more